1. Acetylation-dependent regulation of core spliceosome modulates hepatocellular carcinoma cassette exons and sensitivity to PARP inhibitors.
- Author
-
Sun, Linmao, Liu, Yufeng, Guo, Xinyu, Cui, Tianming, Wu, Chenghui, Tao, Jie, Cheng, Cheng, Chu, Qi, Ji, Changyong, Li, Xianying, Guo, Hongrui, Liang, Shuhang, Zhou, Huanran, Zhou, Shuo, Ma, Kun, Zhang, Ning, Wang, Jiabei, Liu, Yao, and Liu, Lianxin
- Subjects
HEPATOCELLULAR carcinoma ,POLY(ADP-ribose) polymerase ,DEACETYLATION ,DNA damage ,CELL anatomy ,DRUG target - Abstract
Despite the importance of spliceosome core components in cellular processes, their roles in cancer development, including hepatocellular carcinoma (HCC), remain poorly understood. In this study, we uncover a critical role for SmD2, a core component of the spliceosome machinery, in modulating DNA damage in HCC through its impact on BRCA1/FANC cassette exons and expression. Our findings reveal that SmD2 depletion sensitizes HCC cells to PARP inhibitors, expanding the potential therapeutic targets. We also demonstrate that SmD2 acetylation by p300 leads to its degradation, while HDAC2-mediated deacetylation stabilizes SmD2. Importantly, we show that the combination of Romidepsin and Olaparib exhibits significant therapeutic potential in multiple HCC models, highlighting the promise of targeting SmD2 acetylation and HDAC2 inhibition alongside PARP inhibitors for HCC treatment. The relevance of spliceosome core components in cancer is less understood. Here the authors show SmD2, a core component of the spliceosome machinery, is under acetylation-dependent regulation, which could be targeted to enhance sensitivity to PARP inhibitors in hepatocellular carcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF